Nilo Therapeutics

The company targets a neuronal circuit to develop treatments for autoimmune and inflammatory diseases.

Nilo Therapeutics secures $101 million in Series A funding to advance its biotech research. The New York City-based company focuses on using neural circuits to restore immune balance in disease states. This financing supports the scaling of its scientific approach to immune homeostasis.

Oct 2025FinSMEsNews article

Nilo Therapeutics secures $101 million in Series A funding to advance neural circuit therapies. The round is led by investors including The Column Group, DCVC Bio, and Lux Capital, with support from the Gates Foundation and Alexandria Venture Investments. The funding will drive research and development in novel therapeutic approaches targeting neural circuits.

Oct 2025Pharmaceutical Business reviewNews article

Nilo Therapeutics raises **$101 million** to develop autoimmune drugs targeting the **brain-body circuitry** rather than broadly suppressing the immune system. The company introduces a novel class of medicines designed to restore immune balance, differentiating itself from existing treatments. This funding supports preclinical and early-stage research in autoimmune disease therapies.

Oct 2025MedCity NewsNews article

Nilo Therapeutics secures **$101 million in Series A funding** to develop therapies targeting **neural circuits** for restoring immune system balance. The company focuses on **immune homeostasis**, aiming to address dysregulation linked to autoimmune and inflammatory diseases. This funding supports early-stage research in translating neural-immune interactions into clinical applications.

Oct 2025Fierce BiotechNews article